arrow
S

Saori Mishima

Department of Gastrointestinal Oncology
H指数:19
被引数:2,142

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical significance of WES-defined ERBB2 amplification in resectable colorectal cancer

WES定义的ERBB2扩增在可切除结直肠癌中的临床意义

2026-08-200
OAAI
Exploring Health Care Needs and HR-QOL Among Women With Cancer: A Principal Component Analysis Before and 6 Months After Treatment Initiation

探索癌症女性患者的医疗需求与健康相关生活质量:治疗开始前及治疗开始后6个月的主成分分析

2025-10-290
PRE
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer

CLDN18.2阳性胃癌患者接受含zolbetuximab化疗期间早期胃炎的特征分析

2025-09-300
OAAI
ctDNA-based molecular residual disease and survival in resectable colorectal cancer

可切除结直肠癌中基于ctDNA的分子残留疾病和生存

2024-09-161
OAAI
Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer
2024-02-084
OAAI
Atezolizumab following definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
2023-11-010
OA
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: GALAXY study in the CIRCULATE-Japan
2023-11-010
OA
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer

泛亚适应ESMO临床实践指南,用于转移性结直肠癌患者的诊断,治疗和随访

2023-06-0123
OAAI
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

结直肠癌分子残留病变与辅助化疗疗效的研究

2023-01-16183
OAAI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer

泛亚适应ESMO临床实践指南,用于局部结肠癌患者的诊断治疗和随访

2021-12-0156
OAAI
Monitoring molecular residual disease by circulating tumor DNA in resectable colorectal cancer: Molecular subgroup analyses of a prospective observational study GALAXY in CIRCULATE-Japan
2021-07-019
OAAI